他拉唑帕利联合伊立替康±替莫唑胺治疗儿童及年轻成人复发/难治性实体瘤的I期试验
最常见诊断为尤文肉瘤(53%)。A组和B组客观缓解率分别为10.3%和25%,SLFN11阳性与最佳疗效相关,联合方案在尤文肉瘤中可行且有活性。
要点
- 他拉唑帕利联合伊立替康±替莫唑胺在儿童复发/难治性实体瘤中可行。
- A组和B组客观缓解率分别为10.3%和25%。
- SLFN11阳性与最佳治疗反应相关。
核心结论
- 他拉唑帕利联合伊立替康±替莫唑胺在尤文肉瘤中可行且有活性,值得进一步研究。
主要发现
- A组和B组最常见的≥III级血液学毒性分别为中性粒细胞减少(78%和31%)和血小板减少(42%和31%)。
- A组和B组最常见的≥III级非血液学毒性分别为发热性中性粒细胞减少(24%和14%)和腹泻(21%和7%)。
- 6例患者(尤文肉瘤5例,滑膜肉瘤1例)出现缓解(完全缓解1例,部分缓解5例)。
- A组和B组客观缓解率分别为10.3%和25%。
- 药代动力学检测未发现他拉唑帕利与伊立替康之间存在药物相互作用。
关键数值与推荐
- UGT1A1多态性与缓解无关。
- SLFN11免疫组化阳性与最佳治疗反应相关。
临床怎么用
- 该联合方案可用于儿童及年轻成人复发/难治性尤文肉瘤的进一步研究。
- 治疗期间需密切监测中性粒细胞减少、血小板减少、发热性中性粒细胞减少和腹泻等毒性。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Talazoparib combined with irinotecan and temozolomide demonstrated efficacy in a murine Ewing sarcoma model. Based on these data, we conducted a phase I trial of talazoparib and irinotecan with/without temozolomide in paediatric patients with recurrent/refractory solid malignancies. PATIENTS AND METHODS: Cohorts of 3-6 patients with recurrent/refractory solid malignancies received escalating doses of oral talazoparib and intravenous irinotecan (arm A) and oral talazoparib, oral temozolomide and intravenous irinotecan (arm B) in a 3 + 3 design. Talazoparib was administered on days 1-6, and intravenous irinotecan and oral temozolomide were administered on days 2-6, of a 21-day course. Serum for talazoparib and irinotecan pharmacokinetics was obtained during course 1. UGT1A1 polymorphism and Schlafen family member 11 (SLFN11) immunohistochemical staining were performed. RESULTS: Forty-one patients (20 males; median age, 14.6 years; 24 with recurrent disease) were evaluable for dose escalation. Twenty-nine and 12 patients were treated on arm A and arm B, respectively, for a total of 208 courses. The most common diagnosis was Ewing sarcoma (53%). The most common ≥grade III haematologic toxicities in arms A and B included neutropenia (78% and 31%, respectively) and thrombocytopenia (42% and 31%, respectively). In arms A and B, febrile neutropenia (24% and 14%, respectively) and diarrhoea (21% and 7%, respectively) were the most common ≥grade III non-hematologic toxicities. Six patients (Ewing sarcoma [5 patients] and synovial sarcoma [1 patient]) had a response (1 with a complete response, 5 with a partial response). The objective response rates were 10.3% (arm A) and 25% (arm B). Pharmacokinetic testing demonstrated no evidence of drug-drug interaction between talazoparib and irinotecan. UGT1A1 was not related to response. SLFN11 positivity was associated with best response to therapy. CONCLUSIONS: The combination of talazoparib and irinotecan with/without temozolomide is feasible and active in Ewing sarcoma, and further investigation is warranted.
引用
- Federico SM, Pappo AS, Sahr N, et al. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer. 2020. PMID: 32795876. doi:10.1016/j.ejca.2020.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。